NEUROCRINE BIOSCIENCES INC Interest Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Interest Expense of $1.10 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-01.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-01
- NEUROCRINE BIOSCIENCES INC interest expense for the quarter ending 2024-03-31 was $1.10M, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC interest expense for the quarter ending 2023-12-31 was $1.10M, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC interest expense for the quarter ending 2023-09-30 was $1.10M, a 8.33% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC interest expense for the quarter ending 2023-06-30 was $1.30M, a 40.91% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC interest expense for fiscal 2023 was $4.60M, a 35.21% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC interest expense for fiscal 2022 was $7.10M, a 72.48% decline from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC interest expense for fiscal 2021 was $25.80M, a 21.34% decline from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC interest expense for fiscal 2020 was $32.80M, a 2.50% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $1.10M 10-Q · filed 2024-05-01 | $2.20M derived: sum of 2 quarters · filed 2024-05-01 | $3.30M derived: sum of 3 quarters · filed 2024-05-01 | $4.60M derived: sum of 4 quarters · filed 2024-05-01 | ||||
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $2.20M derived: sum of 2 quarters · filed 2024-02-09 | $3.50M derived: sum of 3 quarters · filed 2024-02-09 | $4.60M 10-K · filed 2024-02-09 | ||||
| 2023-09-30 | $1.10M 10-Q · filed 2023-10-31 | $2.40M derived: sum of 2 quarters · filed 2023-10-31 | $3.50M 10-Q · filed 2023-10-31 | $4.60M derived: sum of 4 quarters · filed 2024-05-01 | ||||
| 2023-06-30 | $1.30M 10-Q · filed 2023-08-01 | $2.40M 10-Q · filed 2023-08-01 | $3.50M derived: sum of 3 quarters · filed 2024-05-01 | $4.70M derived: sum of 4 quarters · filed 2024-05-01 | ||||
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-01 | $2.20M derived: sum of 2 quarters · filed 2024-05-01 | $3.40M derived: sum of 3 quarters · filed 2024-05-01 | $5.60M derived: sum of 4 quarters · filed 2024-05-01 | ||||
| 2022-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $2.30M derived: sum of 2 quarters · filed 2024-02-09 | $4.50M derived: sum of 3 quarters · filed 2024-02-09 | $7.10M 10-K · filed 2024-02-09 | ||||
| 2022-09-30 | $1.20M 10-Q · filed 2023-10-31 | $3.40M derived: sum of 2 quarters · filed 2023-10-31 | $6.00M 10-Q · filed 2023-10-31 | $12.60M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $2.20M 10-Q · filed 2023-08-01 | $4.80M 10-Q · filed 2023-08-01 | $11.40M derived: sum of 3 quarters · filed 2024-02-09 | $18.00M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | $2.60M 10-Q · filed 2023-05-03 | $9.20M derived: sum of 2 quarters · filed 2024-02-09 | $15.80M derived: sum of 3 quarters · filed 2024-02-09 | $22.00M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $13.20M derived: sum of 2 quarters · filed 2024-02-09 | $19.40M derived: sum of 3 quarters · filed 2024-02-09 | $25.80M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $6.60M 10-Q · filed 2022-11-01 | $12.80M derived: sum of 2 quarters · filed 2022-11-01 | $19.20M 10-Q · filed 2022-11-01 | $27.00M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $6.20M 10-Q · filed 2022-08-04 | $12.60M 10-Q · filed 2022-08-04 | $20.40M derived: sum of 3 quarters · filed 2023-02-09 | $28.90M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $6.40M 10-Q · filed 2022-05-04 | $14.20M derived: sum of 2 quarters · filed 2023-02-09 | $22.70M derived: sum of 3 quarters · filed 2023-02-09 | $31.00M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $16.30M derived: sum of 2 quarters · filed 2023-02-09 | $24.60M derived: sum of 3 quarters · filed 2023-02-09 | $32.80M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $8.50M 10-Q · filed 2021-11-01 | $16.80M derived: sum of 2 quarters · filed 2021-11-01 | $25.00M 10-Q · filed 2021-11-01 | $33.20M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | $8.30M 10-Q · filed 2021-08-03 | $16.50M 10-Q · filed 2021-08-03 | $24.70M derived: sum of 3 quarters · filed 2022-02-11 | $32.70M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $8.20M 10-Q · filed 2021-05-05 | $16.40M derived: sum of 2 quarters · filed 2022-02-11 | $24.40M derived: sum of 3 quarters · filed 2022-02-11 | $32.30M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $16.20M derived: sum of 2 quarters · filed 2022-02-11 | $24.10M derived: sum of 3 quarters · filed 2022-02-11 | $32.00M 10-K · filed 2022-02-11 | $31.96M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $8.00M 10-Q · filed 2020-11-09 | $8.04M 10-Q · filed 2019-11-04 | $15.90M derived: sum of 2 quarters · filed 2020-11-09 | $23.80M 10-Q · filed 2020-11-09 | $23.83M 10-Q · filed 2019-11-04 | $31.53M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-06-30 | $7.90M 10-Q · filed 2020-08-03 | $7.94M 10-Q · filed 2019-07-29 | $15.80M 10-Q · filed 2020-08-03 | $15.79M 10-Q · filed 2019-07-29 | $23.53M derived: sum of 3 quarters · filed 2021-02-05 | $31.20M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-03-31 | $7.90M 10-Q · filed 2020-05-06 | $7.85M 10-Q · filed 2019-04-29 | $15.63M derived: sum of 2 quarters · filed 2021-02-05 | $23.30M derived: sum of 3 quarters · filed 2021-02-05 | $30.90M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $7.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $15.40M derived: sum of 2 quarters · filed 2021-02-05 | $23.00M derived: sum of 3 quarters · filed 2021-02-05 | $30.50M 10-K · filed 2021-02-05 | $30.53M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $7.67M 10-Q · filed 2019-11-04 | $15.26M derived: sum of 2 quarters · filed 2019-11-04 | $22.77M 10-Q · filed 2019-11-04 | $30.19M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | $7.59M 10-Q · filed 2019-07-29 | $15.10M 10-Q · filed 2019-07-29 | $22.51M derived: sum of 3 quarters · filed 2020-02-07 | $29.85M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | $7.50M 10-Q · filed 2019-04-29 | $14.92M derived: sum of 2 quarters · filed 2020-02-07 | $22.26M derived: sum of 3 quarters · filed 2020-02-07 | $27.03M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $14.76M derived: sum of 2 quarters · filed 2020-02-07 | $19.52M derived: sum of 3 quarters · filed 2020-02-07 | $19.52M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $7.34M 10-Q · filed 2018-11-05 | $12.10M derived: sum of 2 quarters · filed 2018-11-05 | $12.10M 10-Q · filed 2018-11-05 | $12.10M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | $4.77M 10-Q · filed 2018-07-31 | $4.77M 10-Q · filed 2018-07-31 | $4.77M derived: sum of 3 quarters · filed 2019-02-08 | $4.77M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | $0.00 derived: sum of 2 quarters · filed 2019-02-08 | $0.00 derived: sum of 3 quarters · filed 2019-02-08 | $0.00 derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $0.00 derived: sum of 2 quarters · filed 2019-02-08 | $0.00 derived: sum of 3 quarters · filed 2019-02-08 | $0.00 10-K · filed 2019-02-08 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |